Shanghai Pharmaceuticals is the biggest drug importer in China and the second largest distributor of pharmaceuticals. Shanghai Pharmaceuticals generates $37 billion in total revenue and produces medications for cancer, diabetes, cardiovascular...
India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030. CPHI & P-MEC India exemplifies this growth by connecting global and domestic stakeholders to showcase...
Aptar is assisting Indian pharmaceutical firms in the launch of inhalers and nasal sprays for both local and export markets. Aptar is the top global supplier of inhalation devices, essential for administering medications used to manage respiratory...
In 2023, international pharmaceutical firms supplied clinical trial medications to local patients valued at approximately 320.8 billion. The overall quantity of clinical trials carried out that year was 1,723, reflecting a 7.7 percent rise...
The US investments mark the initial phase of significant actions aimed at supporting AstraZeneca's goal of reaching $80 billion in overall revenue by 2030, as outlined in May of this year. An essential aspect of our approach is hastening the...
Among the leading 10 therapies that account for over 90% of the Indian pharmaceutical market, price was the key factor in the expansion of the cardiac sector. The anti-hypertensive medications, comprising nearly 50% of the cardiac sector, are...
India is presently the fourth largest medical device market in Asia, boasting an industry valued at USD 14 billion and exports totaling USD 3.7 billion. The MedTech program is expected to assist local manufacturers in expanding the market value to...
The Indian pharmaceutical market (IPM) experienced a 6.1 percent value increase in October 2024, with significant therapies demonstrating favorable value growth, as per a report from market research firm Pharmarack. Among these areas, the cardiac...
SystImmune, Inc (SystImmune), a biotechnology company in the clinical stage, declared that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC)...
Moderna, Inc., a pioneer in mRNA medicine development, revealed that Health Canada has authorized mRESVIA (mRNA vaccine for Respiratory Syncytial Virus) for active immunization aimed at preventing lower respiratory tract infections caused by...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")